Peer-reviewed veterinary case report
Dog developed heart muscle disease after lymphoma chemo
By Tagawa, Michihito et al.·Published in Open veterinary journal·2021·Obihiro University of Agriculture and Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cardiomyopathy in a dog with multicentric lymphoma following treatment with several anthracyclines.
- Species:
- dog
Plain-English summary
An 8-year-old mixed-breed dog was diagnosed with lymphoma and initially responded well to chemotherapy, going into remission. However, after receiving a specific chemotherapy drug called epirubicin, the dog developed dilated cardiomyopathy, a serious heart condition. Despite treatment with heart medications that helped stabilize the dog, the lymphoma returned, and sadly, the dog passed away shortly after the heart diagnosis. This case highlights the potential heart risks associated with certain chemotherapy drugs used in treating lymphoma in dogs.
People also search for: dog lymphoma treatment · dog heart problems after chemotherapy · anthracycline side effects in dogs
Abstract
BACKGROUND: Canine lymphoma is one of the most frequently occurring malignant neoplasms in dogs. Anthracycline-based chemotherapy for the treatment of canine lymphoma is very effective; however, there is not enough evidence for the development of cardiac toxicity using several anthracyclines as chemotherapeutic agents. CASE DESCRIPTION: An 8-year-old, castrated, mixed-breed dog was diagnosed with multicentric lymphoma and received multi-agent chemotherapy. Complete remission was achieved, but the patient had a relapse of lymphoma. After third-line chemotherapy with epirubicin, the patient was diagnosed with dilated cardiomyopathy. The total cumulative doses of doxorubicin, mitoxantrone, and epirubicin were 125, 8, and 125 mg/m, respectively. Although the patient was treated with cardiac drugs and clinically stabilized, the patient had a relapse of lymphoma and died shortly after the diagnosis of cardiomyopathy. CONCLUSION: The patient was suspected to have anthracycline-induced cardiomyopathy. Further studies are required to establish prevention and management strategies for dogs receiving potentially cardiotoxic therapies, such as anthracyclines.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33898277/